Skip to content

Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA

Sandoz Submits 351(k) Application for Biosimilar Natalizumab to Treat MS

New Biosimilar Product Checklist

Monograph Presentation Checklist

P&T Implementation Checklist

How to select a best-value biological medicine? A practical model to support hospital pharmacists

Healthcare system conversion to a biosimilar: Trials and tribulations

A Patient’s Guide to Understanding Biosimilars

Formulary Monograph Services

Biosimilars in the U.S.: Reimbursement and Impacts to Uptake